ZYDUSLIFENSEZydus Lifesciences Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Thu, 6 Nov, 2025 · 13:03 IST

Zydus September quarter profit rises 38 percent on higher sales

Pat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDFExplain this filing

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-4.0%Reaction day
₹973.40
prior close
₹957.75
announcement price
In-mkt
timing
Nifty 100market · index membership as recorded later (tracked since Jun 2026)-0.5%-3.5% vs market
Pharmaceuticals peers, median of 156sector-1.1%-2.9% vs sector

On the reaction day the stock moved 3.5 pts less than Nifty 100 and 2.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+1.1
10m
+0.1
15m
+0.5
30m
-0.4
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-4.0-0.5-3.5-1.1-2.9
Next day
-2.9-0.5-2.4-1.4-1.6
2d
-2.7-0.2-2.5-2.0-0.7
3d
-3.6+0.2-3.8-2.3-1.3
4d
-2.3+0.8-3.1-1.2-1.1
5d
-2.9+0.8-3.7-1.5-1.4
1w
-3.9+1.4-5.3-1.7-2.3
15d
-3.5+1.7-5.3-4.3+0.8
1m
-5.3+0.5-5.8-7.0+1.7
2m
-4.3+2.0-6.3-5.2+0.9
3m
-8.9+0.0-8.9-9.1+0.3
UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zydus reported unaudited consolidated sales of INR 6,123.2 crore in the September 2025 quarter, up 16.9 percent year on year. Net profit rose 38.3 percent to INR 1,258.6 crore. Half year sales rose 10.9 percent to INR 12,696.9 crore, while profit rose 16.9 percent to INR 2,725.4 crore. Results included INR 34.2 crore of one-time charges. Amplitude and Comfort Click were acquired. Deloitte's limited review found no material issue.

Likely market impact

Strong profit growth may support the stock, but higher borrowings and one-time charges add risk.